No abstract available
Plain language summary
This study evaluates the frequency of terminal disclaimers filed by drug patent holders to obviate obviousness-type double patenting rejections associated with drug patent thickets.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Biosimilar Pharmaceuticals / economics
-
Drug Industry* / economics
-
Drug Industry* / legislation & jurisprudence
-
Drugs, Generic / economics
-
Economic Competition / economics
-
Economic Competition / legislation & jurisprudence
-
Fees, Pharmaceutical / legislation & jurisprudence
-
Patents as Topic*
-
United States
Substances
-
Biosimilar Pharmaceuticals
-
Drugs, Generic